CytoDyn Hit with Securities Class Action Over Alleged ‘Hyping’ of HIV Therapy as Potential COVID-19 Treatment
April 14, 2021 CytoDyn and its CEO and CFO face a class action over what investors call the biotech company’s “aggressive” hyping of its potential HIV therapy Leronlimab as a possible treatment for COVID-19.